QuidelOrtho Corp
QDEL28.580USD
-0.380-1.31%
Cierre 04/29, 16:00（ET）Cotizaciones retrasadas 15 min
1.92BCap. mercado
PérdidaP/E TTM
Más Datos de QuidelOrtho Corp Compañía
QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
Información de la empresa
Código de la empresaQDEL
Nombre de la empresaQuidelOrtho Corp
Fecha de salida a bolsaFeb 01, 1991
Fundada en2021
Director ejecutivoMr. Brian J. Blaser
Número de empleados6600
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 01
Dirección9975 Summers Ridge Road
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92121
Teléfono18585521100
Sitio Webhttps://www.quidelortho.com/
Código de la empresaQDEL
Fecha de salida a bolsaFeb 01, 1991
Fundada en2021
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
89.24K
--
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
67.62K
--
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.16K
+9.93%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
19.17K
+20.97%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
15.70K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
8.13K
--
Ms. Evelyn S. Dilsaver
Ms. Evelyn S. Dilsaver
Independent Director
Independent Director
--
--
Mr. Lee Bowman
Mr. Lee Bowman
Chief Human Resources Officer
Chief Human Resources Officer
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph D. Wilkins, Jr.
Mr. Joseph D. Wilkins, Jr.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Kenneth F. Buechler, Ph.D.
Dr. Kenneth F. Buechler, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
89.24K
--
Dr. Matthew W. Strobeck, Ph.D.
Dr. Matthew W. Strobeck, Ph.D.
Independent Director
Independent Director
67.62K
--
Ms. Michelle A. Hodges, J.D.
Ms. Michelle A. Hodges, J.D.
Senior Vice President, Corporate Secretary, Chief Legal Officer
Senior Vice President, Corporate Secretary, Chief Legal Officer
23.16K
+9.93%
Mr. Joseph M. Busky
Mr. Joseph M. Busky
Chief Financial Officer
Chief Financial Officer
19.17K
+20.97%
Mr. Edward L. (Ed) Michael
Mr. Edward L. (Ed) Michael
Independent Director
Independent Director
15.70K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
8.13K
--
Desglose de ingresos
Divisa: USDHora de actualización: dom., 6 de abr
Divisa: USDHora de actualización: dom., 6 de abr
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.57B
56.37%
Foreign
1.21B
43.63%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Labs
1.43B
51.27%
Point-of-Care
694.10M
24.94%
Immunohematology
522.60M
18.78%
Donor Screening
115.50M
4.15%
Molecular Diagnostic Solutions
24.00M
0.86%
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
T. Rowe Price Investment Management, Inc.
16.66%
BlackRock Institutional Trust Company, N.A.
11.54%
The Vanguard Group, Inc.
10.08%
Rubric Capital Management LP
8.23%
Invesco Advisers, Inc.
4.78%
Other
48.71%
Estadísticas de accionistas
Accionista
Proporción
T. Rowe Price Investment Management, Inc.
16.66%
BlackRock Institutional Trust Company, N.A.
11.54%
The Vanguard Group, Inc.
10.08%
Rubric Capital Management LP
8.23%
Invesco Advisers, Inc.
4.78%
Other
48.71%
Tipo
Accionista
Proporción
Investment Advisor
46.62%
Investment Advisor/Hedge Fund
38.01%
Hedge Fund
20.96%
Research Firm
1.63%
Sovereign Wealth Fund
1.20%
Pension Fund
1.19%
Individual Investor
0.78%
Bank and Trust
0.59%
Family Office
0.15%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
709
74.95M
111.12%
-12.34M
2024Q4
747
75.07M
111.30%
-13.02M
2024Q3
744
73.58M
109.44%
-4.02M
2024Q2
767
70.18M
104.79%
-7.57M
2024Q1
799
67.05M
100.24%
-5.28M
2023Q4
828
68.21M
102.09%
-2.95M
2023Q3
842
70.19M
105.17%
-4.01M
2023Q2
860
68.99M
103.61%
-6.94M
2023Q1
894
68.68M
103.29%
-6.80M
2022Q4
939
69.19M
108.75%
-5.89M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Investment Management, Inc.
11.24M
16.66%
+1.84M
+19.59%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.79M
11.54%
+1.09M
+16.28%
Dec 31, 2024
The Vanguard Group, Inc.
6.80M
10.08%
-21.19K
-0.31%
Dec 31, 2024
Rubric Capital Management LP
5.55M
8.23%
+1.35M
+32.14%
Dec 31, 2024
Invesco Advisers, Inc.
3.23M
4.78%
+1.44M
+81.05%
Dec 31, 2024
State Street Global Advisors (US)
2.27M
3.37%
+366.13K
+19.19%
Dec 31, 2024
ArrowMark Colorado Holdings, LLC
1.98M
2.93%
+100.52K
+5.35%
Dec 31, 2024
D. E. Shaw & Co., L.P.
1.73M
2.56%
+50.77K
+3.03%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.25M
1.85%
+30.51K
+2.50%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
1.22M
1.8%
+107.78K
+9.72%
Dec 31, 2024
Ver más
ETFs relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Invesco S&P SmallCap Health Care ETF
1.57%
SPDR S&P Health Care Equipment ETF
1.45%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.89%
Ballast Small/Mid Cap ETF
0.48%
WisdomTree US SmallCap Quality Growth Fund
0.39%
SPDR S&P 600 Small Cap Value ETF
0.34%
iShares S&P Small-Cap 600 Value ETF
0.33%
VictoryShares US Small Mid Cap Value Momentum ETF
0.28%
Avantis US Small Cap Value ETF
0.27%
JPMorgan Fundamental Data Science Mid Core ETF
0.26%
Ver más
Invesco S&P SmallCap Health Care ETF
Proporción1.57%
SPDR S&P Health Care Equipment ETF
Proporción1.45%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.89%
Ballast Small/Mid Cap ETF
Proporción0.48%
WisdomTree US SmallCap Quality Growth Fund
Proporción0.39%
SPDR S&P 600 Small Cap Value ETF
Proporción0.34%
iShares S&P Small-Cap 600 Value ETF
Proporción0.33%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporción0.28%
Avantis US Small Cap Value ETF
Proporción0.27%
JPMorgan Fundamental Data Science Mid Core ETF
Proporción0.26%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos